All News
Best of 2023: 25 Great Women in Rheumatology
This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?
Read Article
Best of 2023: Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
Read Article
Best of 2023: Our old friend, hydroxychloroquine
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
Read Article
NVC in 1356 #SSc registry pts classified as early, active or‘late. Late pattern seen in 40%: signific. assoc w/ dcSSc (OR=1.96), ILD (OR=1.29), renal crisis (OR=3.46), digital ulcer (OR=1.29), & topoisomerase I Abs (OR=1.39) https://t.co/RgET0HbImf https://t.co/Ex3nKto6JW
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 365 RA pts showed eating half a pizza >1 time/wk (vs. ≤2 times/mo) was assoc w/ 70% less Dz activity; esp w/ more severe RA (80%) (benefit likely due to mozzarella & olive oil). YES, this was an italian study... https://t.co/1yHtS1wrtn https://t.co/xoxKK6ujdk
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Bimekizumab is Coming…in Third Place
Of the many exciting advancements for patients with psoriatic arthritis at ACR23 one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab.
https://t.co/rhyEuyCjQI https://t.co/vbRs2144We
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Methotrexate: shall we split up?
Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg.
https://t.co/EQV2LeaaGB https://t.co/bD2zJbXETv
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/7SgvYqFe1W
Dr. John Cush RheumNow ( View Tweet)
Promising Therapies for Sjogren's
Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/qwRRf0sYhj https://t.co/zZACPJ96NM
Dr. John Cush RheumNow ( View Tweet)
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/NL8yJ9CdvQ https://t.co/dUUXyWYbsT
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Eosinophilia in RA
High Eosinophil counts in Stable RA - what's the differential Dx?.
https://t.co/r7DHil4u9B https://t.co/rTAGUcgd1C
Dr. John Cush RheumNow ( View Tweet)
Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/xOYfEs16ou https://t.co/MzEPpUc7Eb
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Recommendations on Fatigue
Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life.
https://t.co/ETYyCnykj7 https://t.co/c2DEWrvqZb
Dr. John Cush RheumNow ( View Tweet)
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/iBIreoNrXx https://t.co/xh4rWdKbGT
Dr. John Cush RheumNow ( View Tweet)
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/rJSqLwQW1S https://t.co/w3ZpdVQYNL
Dr. John Cush RheumNow ( View Tweet)
Hemophagocytic Lymphohistiocytosis in Still's disease
Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/8XvMsGtul2 https://t.co/HG0QOu5V77
Dr. John Cush RheumNow ( View Tweet)
FDA Warning on CAR-T Cell Therapy
The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
https://t.co/uxY7xgqgqn https://t.co/xyZrXXGGIy
Dr. John Cush RheumNow ( View Tweet)
Korean ULTRA registry studied 117 Gout pts starting ULT; compared T2T achievers (SUA< 6) vs non-achievers. @6 mos, 71% reached target SUA (w/ better adherence (98% vs. 76%) than non-achievers. T2T achievers assoc w/ good adherence, +FamHx, & HTN meds https://t.co/wTuvPqcan5 https://t.co/QD9j923sSa
Dr. John Cush RheumNow ( View Tweet)
Metanalysis shows the prevalence of self-reported sleep problems in #PsA ranged 30% to 85%. 6 studies showed poor sleep quality in 73% (statistically higher than controls 27%). Sleep ranked in the top 4 health-related quality of life domains by PsA pts. https://t.co/d79Ji3KCBu https://t.co/HJpqUIQ8x6
Dr. John Cush RheumNow ( View Tweet)
FINAL DAY for early bird pricing for RheumNow Live.
Take advantage of this discounted price TODAY!
https://t.co/UW9SMjEBYB https://t.co/DX2SJZYkUW
Links:
Dr. John Cush RheumNow ( View Tweet)
